The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016.

dc.contributor.authorJocelyn Moyes
dc.contributor.authorStefano Tempia
dc.contributor.authorSibongile Walaza
dc.contributor.authorMeredith L. McMorrow3
dc.contributor.authorFlorette Treurnicht4 Nicole Wolter
dc.contributor.authorAnne von Gottberg
dc.contributor.authorKathleen Kahn6
dc.contributor.authorAdam L Cohen
dc.contributor.authorHalima Dawood
dc.contributor.authorEbrahim Variava
dc.contributor.authorCheryl Cohen
dc.description.abstractIntroduction Data on the economic burden of RSV-associated illness will inform decisions on the programmatic implementation of maternal vaccines and monoclonal antibodies. We estimated these costs in fine age bands to allow more accurate cost-effectiveness models to account for limited duration of protection conferred by short or long acting interventions. Methods We conducted a costing study at sentinel sites across South Africa to estimate out-of-pocket and indirect costs for RSV-associated mild and severe illness. We collected facility-specific costs for staffing, equipment, services, diagnostic tests and treatment. Using case-based data we calculated a patient day equivalent (PDE) for RSV-associated hospitalisations or clinic visits; the PDE was multiplied by the number of days of care to provide a case-cost to the healthcare system. We estimated the costs in 3-month age intervals in children aged <1 years and as a single group for children aged 1-4 years. We then applied our data to a modified version of the World Health Organization tool for estimating mean annual national cost burden, including medically and non-medically attended RSV-associated illness. Results The estimated mean annual cost of RSV-associated Illness in children aged <5 years was United States dollars ($)137 204 393, of which 81% ($111 742 713) were healthcare system incurred, 6% ($8 881 612) were out of pocket expenses and 13% ($28 225 801) were indirect costs. Thirty-three percent ($45 652 677/$137 204 393) of the total cost in children aged <5 years was in the <3-month age group, of which 52% ($71 654 002) were healthcare system incurred. The costs of non-medically attended cases increased with age from $3 307 218 in the <3-month age group to $8 603 377 in the 9-11-month age group. Conclusion Among children <5 years of age with RSV in South Africa, the highest cost burden was in young infants; therefore, interventions against RSV targeting this age group are important to reduce the health and cost burden of RSV-associated illness.
dc.facultyFaculty of Health Sciences
dc.schoolPublic Health
dc.titleThe economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016.
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
101.44 KB
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
2.43 KB
Item-specific license agreed upon to submission